Comparative Pharmacology
Head-to-head clinical analysis: DANAZOL versus ORA TESTRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANAZOL versus ORA TESTRYL.
DANAZOL vs ORA-TESTRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.
Testosterone replacement therapy; binds to androgen receptors, promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
300-600 mg orally twice daily; maximum 800 mg/day
Intramuscular injection: 50-100 mg every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life is 4-4.5 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
Clinical Note
moderateDanazol + Tolbutamide
"The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Rosiglitazone
"The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Pioglitazone
"The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Danazol."
Clinical Note
moderateDanazol + Saxagliptin
Terminal half-life 2.5-3.5 hours; clinical context: requires multiple daily dosing to maintain steady-state levels
Primarily hepatic metabolism; approximately 60% excreted in feces, 30% in urine as metabolites.
Renal (90% as glucuronide and sulfate conjugates, 10% unchanged); Biliary/fecal (10%)
Category C
Category C
Androgen/Antigonadotropin
Androgen
"The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Danazol."